Results 201 to 210 of about 212,526 (280)

Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Hetta HF, Salama A, Aljuaid TA, Mojmami YT, Alotibi RS, Alqabaly AM, Aldosari NA, Alshahri SA, Asiri WIA, Alamri RS, Alanazi FA, Alenazi MSA, Albuhayri MH, Ramadan YN, Sayad R.   +14 more
europepmc   +1 more source

Finding the perfect spot for fluorine: Improving potency up to 40-fold during a rational fluorine scan of a Bruton’s Tyrosine Kinase (BTK) inhibitor scaffold

, 2014
Yan Lou, Zachary K. Sweeney, A. Kuglstatter, Dana Davis, David Goldstein, Xiaochun Han, Jun‐Bae Hong, Buelent Koçer, Rama K. Kondru, Renée Litman, Joel McIntosh, Keshab Sarma, Judy M. Suh, Joshua P. Taygerly, Timothy D. Owens   +14 more
openalex   +1 more source

Novel deletion mutation in Bruton’s tyrosine kinase results in X-linked agammaglobulinemia: A case report

, 2020
Xiaomei Hu, Ke Yuan, Hong Chen, Chun Chen, Yanlan Fang, Jianfang Zhu, Li Liang, Chunlin Wang   +7 more
openalex   +1 more source

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study. [PDF]

Cureus
Ito A, Ito K, Iriyama C, Goto N, Inamoto Y, Okamoto M, Hirose Y, Morisaku M, Yamada S, Hayakawa N, Tomita A.   +10 more
europepmc   +1 more source

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Cancer Research, 2016
Andrew Stiff, P. Trikha, R. Wesolowski, K. Kendra, Vincent Hsu, Sarvani Uppati, Elizabeth L. McMichael, Megan C. Duggan, Amanda R. Campbell, Karen A. Keller, I. Landi, Y. Zhong, J. Dubovsky, J. H. Howard, Lianbo Yu, Bonnie K. Harrington, M. Old, S. Reiff, T. Mace, S. Tridandapani, N. Muthusamy, M. Caligiuri, J. Byrd, W. Carson   +23 more
semanticscholar   +1 more source

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar, Ashlee Joseph, Taylor R. Brooks, Brian T. Hill, David Bond, Kami J. Maddocks, Alexey V. Danilov, Christine Argao, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey I. Harris, Javier Muñoz, Philip R. Young, Craig A. Portell, Patrick M. Reagan, Christine E. Ryan, Reid W. Merryman, Arash Velayati, I. Brian Greenwell, Drew G. Gerber, Preetesh Jain, Michael Wang, Sabarish R. Ayyappan, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur S. Narkhede, Amitkumar Mehta, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin   +55 more
openalex   +1 more source

Bruton’s Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages [PDF]

, 2018
Lindsay E. Nyhoff, Emily S. Clark, Bridgette L. Barron, Rachel H. Bonami, Wasif N. Khan, Peggy L. Kendall   +5 more
openalex   +1 more source

Pharmacologic Inhibition of Bruton's Tyrosine Kinase Attenuates Experimental Abdominal Aortic Aneurysms

JVS - Vascular Science, 2020
Baohui Xu, Yankui Li, Gang Li, Yingbin Ge, Jia Guo, Weirong Fang, Wei Wang, Fanru Shen, Takahiro Shoji, Toru Ikezoe, Xiaoya Zheng, Sihai Zhao, Xiaofeng Chen, Masaaki Miyata, Alan Daugherty, Hong Lu, Ronald L. Dalman   +16 more
doaj   +1 more source